Heron Therapeutics is trading 5.63% down at $0.33, amid recent competitive pressure and uncertainty surrounding potential generic CINVANTI entry.
- No major company-specific announcement dated September 9, 2026 was identified in available coverage.
- The broader market is also weaker amid geopolitical tensions, higher oil prices, and rate concerns.
- The market decline is not sufficient to clearly explain Heron Therapeutics’ sharper drop.